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Abstract
Background: An inverse association between birth weight and the risk of developing type 2
diabetes (T2D) in adulthood has been reported. This association may be explained by common
genetic variants related to insulin secretion and resistance, since insulin is the most important
growth factor in fetal life. The objective of this study was to examine whether T2D gene
polymorphism TCF7L2 rs7903146 is associated with growth patterns from fetal life until infancy.
Methods: This study was performed in two independent birth cohort studies, one prospective
population-based (Generation R), and one of subjects born small-for-gestational-age (SGA cohort).
Fetal growth was assessed by ultrasounds in second and third trimesters of pregnancy in
Generation R. Growth in infancy was assessed in both cohorts at birth and at 6, 12 and 24 months
postnatally. TCF7L2 genotype was determined in 3,419 subjects in Generation R and in 566 subjects
in the SGA cohort.
Results: Minor allele frequency did not differ significantly (p = 0.47) between Generation R (T-
allele: 28.7%) and the SGA cohort (T-allele: 29.8%). No differences at birth were found in
gestational age or size (head circumference, length, weight) between the genotypes in either
cohort. TCF7L2 genotype was also not associated with any pre- or postnatal growth characteristic
in either Generation R or the SGA cohort.
Conclusion: We found no evidence for an association between TCF7L2 genotype and fetal and
early postnatal growth. Furthermore, this TCF7L2 polymorphism was not associated with an
increased risk of SGA.
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Several epidemiological studies have shown inverse asso-
ciations between birth weight and metabolic diseases,
including type 2 diabetes (T2D) in adulthood [1,2]. These
associations may be influenced by common genetic vari-
ants [2]. Insulin is the most important fetal growth factor
and insulin-mediated fetal growth might be affected by
genetic polymorphisms that regulate fetal insulin secre-
tion or insulin sensitivity [2]. Therefore, gene variants
associated with T2D have been suggested as candidate
genes for influencing early growth [2].
Genome-wide association (GWA) studies have consist-
ently shown that the C>T substitution in TCF7L2 gene
(rs7903146) increases the risk of T2D approximately 2-
fold when two risk allele copies (TT) are present [3-5]. The
T-allele of this TCF7L2 polymorphisms has been suggest
to reduce proinsulin to insulin conversion [6], though the
exact mechanism has not been elucidated yet. Other sin-
gle nucleotide polymorphisms (SNPs) of the TCF7L2 gene
have been shown to be associated with type 2 diabetes,
although less strongly [7]. The T-allele of rs7903146,
which according to HapMap has an allele frequency
amongst Caucasians (CEU) of 28% [8], has been shown
to be associated with reduced insulin response and secre-
tion in both diabetic and non-diabetic individuals [9-11],
though results in non-diabetics are not consistent [12].
This polymorphism may also lead to an increased risk of
gestational diabetes [13]. Such findings make TCF7L2 one
of the most important candidate genes for explaining the
associations between low birth weight and T2D.
Freathy et al. were the first to investigate the association
between TCF7L2 genotype and birth weight, and they
found an association with maternal TCF7L2 genotype
[14]. Each maternal copy of the risk allele was associated
with a 30 grams increase in offspring birth weight, proba-
bly as a result of higher maternal glucose levels stimulat-
ing fetal insulin production [14]. After adjustment for
maternal genotype, fetal TCF7L2 genotype did not influ-
ence fetal birth weight [14]. This finding was replicated in
the Helsinki birth cohort [15]. In another study, no asso-
ciation was found between fetal TCF7L2 genotype and the
risk of small size for gestational age [16]. Birth weight
might be an inappropriate measure of the individual
growth potential since different fetal growth rates may
lead to the same birth weight [17]. Furthermore, rapid
postnatal weight gain, especially in fat mass, has also been
shown to be associated an increase risk of obesity and type
2 diabetes in later life, independent of birth weight
[18,19].
Therefore we hypothesized that longitudinally measured
fetal and postnatal growth are better parameters in the
investigation of the possible effect of TCF7L2 on growth
than specific growth characteristic such as birth weight.
We first assessed the associations of TCF7L2 rs7903146
with fetal and postnatal growth characteristics in a popu-
lation-based prospective cohort study among 3,419 sub-
jects followed from early fetal life onwards. Second, we
assessed associations of this genotype with birth weight
and postnatal growth in 566 small-for-gestational-age
(SGA) children participating in an independent cohort
study.
Methods
Cohort Descriptions
The Generation R Study
The Generation R Study is a population based prospective
cohort study from early fetal life onwards. The study is
designed to identify early environmental and genetic
determinants of growth, development and health from
fetal life until young adulthood. It has been described pre-
viously in detail [20,21]. Fetal and postnatal growth and
their main determinants were repeatedly measured by
physical examinations, fetal ultrasounds, biological sam-
ples and questionnaires. We have previously shown that
of all eligible children born in the study area 61% partici-
pated in the study [21]. The study has been approved by
the Medical Ethics Committee of the Erasmus Medical
Center, Rotterdam. Written informed consent was
obtained from all participants or their parents.
Fetal growth and birth characteristics
Fetal ultrasound examinations were carried out during vis-
its to one of the research centers. These fetal ultrasounds
were used for establishing gestational age in the first tri-
mester of pregnancy (conception to 12 weeks of gesta-
tional age), as well as for assessing fetal growth
characteristics in second (17–25 weeks of gestational age)
and third trimesters (> 25 weeks of gestational age) of
pregnancy [22]. Fetal growth measurements used in the
present study included head circumference (HC), abdom-
inal circumference (AC) and femur length (FL) measured
in second and third trimesters to the nearest mm using
standardized ultrasound procedures [23]. Estimated fetal
weight (EFW) was calculated by means of the formula
from Hadlock using head circumference, abdominal cir-
cumference and femur length (log10 EFW = 1.5662 –
0.0108 (HC) + 0.0468 (AC) + 0.171 (FL) + 0.00034 (HC)2
– 0.003685 (AC * FL)) [24]. First trimester ultrasound
measures were not included for assessing growth charac-
teristics because these ultrasound examinations were pri-
marily performed to establish gestational age.
Birth and postnatal growth
Birth weight, date of birth and gender were obtained from
community midwife and hospital registries. Information
on head circumference or length at birth was not availa-
ble, but many children were measured during the first two
months of life. Well-trained staff in community health
centers obtained postnatal growth characteristics usingPage 2 of 8
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program, the visits at which these growth characteristics
were measured were grouped into three age periods: 6
months (range 5 to 8.99); 12 months (range 9 to 12.99);
and 24 months (range 23 to 34.99 months). Postnatally,
head circumference was not measured at the age of 24
months.
Population for analysis
Analyses were restricted to singletons from whom DNA
was available for TCF7L2 genotyping and who also had
Dutch or other Caucasian ethnicity as defined by having
both parents born in the Netherlands or another Euro-
pean country (n = 3,419) (Figure 1). Fetal growth meas-
urements were available for 3,320 and 3,384 children in
second and third trimesters, respectively. Of these chil-
dren, those living outside the study area postnatally
(10%) were not followed up in infancy and a further 12%
were lost during postnatal follow-up, leaving 2,675 sub-
jects eligible for the postnatal analyses (Figure 1).
The SGA Cohort
The SGA cohort was designed for the purpose of assessing
growth and development of subjects born SGA. Subjects
were included at childhood age (n = 367) or at young
adult age (n = 252). Children were included in the SGA
cohort when they were SGA at birth, had short stature
(height standard deviation score (SDS) for age and gender
of below – 2 [25]), did not show catch-up growth in
height, and had no growth failure caused by any other
identified disorder. These inclusion criteria have previ-
ously been described [26]. Young adults included in the
SGA cohort were randomly selected from hospitals in the
Netherlands, where they had been registered because of
being SGA. Only those young adults born at 36 weeks or
more of gestation, being singleton and Caucasian and not
suffering from conditions or receiving treatment known
to interfere with growth, were invited to participate. SGA
was defined as a birth length and/or birth weight SDS of
below -2.0 for gestational age [27]. The Medical Ethics
Committees of Erasmus Medical Center, Rotterdam, and
of the participating centers approved all studies and writ-
ten informed consent was obtained from all participants
or their parents.
Birth and postnatal growth
Birth characteristics of the SGA cohort were collected from
hospital registries. The gestational age of the subjects was
determined by ultrasound in the first trimester, if availa-
ble, and otherwise calculated from the date of the last
menstruation. Growth data (head circumference, height
and weight) measured during the first two years of life
were collected from records of hospitals, community
health services and general practitioners. Longitudinal
growth data were available in 272 participants in the SGA
cohort (Figure 1).
Genotyping
DNA was collected from cord blood samples in the Gen-
eration R cohort and from peripheral venous blood sam-
ples in the SGA cohort. Cord blood for DNA isolation was
available for 59% of all participating children of the Gen-
eration R cohort. When cord blood samples were missing,
this result was mainly due to logistical constraints at the
delivery. Venous blood samples were available in the
complete SGA cohort. Genotyping of the C>T substitution
in TCF7L2 (rs7903146) gene was performed using Taq-
man allelic discrimination assay (Applied Biosystems,
Foster City, CA) and Abgene QPCR ROX mix (Abgene,
Hamburg Germany). The genotyping reaction was ampli-
fied using the GeneAmp® PCR system 9600 (95°C (15
minutes), with 40 cycles of 94°C (15 seconds) and 60°C
(1 minute)). The fluorescence was detected on the
7900HT Fast Real-Time PCR System (Applied Biosystems)
Flow diagram indicating number of subjects in the two cohortsigure 1
Flow diagram indicating number of subjects in the two cohorts. * All live-born, Caucasian, singleton subjects within 
Generation R.
The SGA Cohort 
n = 619 
TCF7L2 (rs7903146) 
genotype available  
n = 566 
Postnatal follow-up 
n = 272 
No postnatal follow-up 
n = 294 
No genotype available 
n = 53  
The Generation R Cohort* 
n = 5,341 
TCF7L2 (rs7903146) 
genotype available  
n = 3,419 
Postnatal follow-up 
n = 2,675 
No postnatal follow-up 
n = 744 
No genotype available 
n = 1,922 Page 3 of 8
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software (version 2.3, Applied Biosystems). Genotyping
was successful in 98% and 91% of the samples in the Gen-
eration R and SGA cohort, respectively. To confirm the
accuracy of the genotyping results, 276 randomly selected
samples from the Generation R Study were genotyped for
a second time with the same method. The error rate was
less than 1%. The frequency distribution in Generation R
did not deviate from the Hardy-Weinberg equilibrium in
subjects with Dutch ethnicity nor did it deviate in the SGA
cohort.
Data analysis
With sample sizes in the Generation R Study of 3,419 and
2,675 subjects for fetal and postnatal analyses respec-
tively, and assuming a statistical power level (1 – β) of
0.80, a level of significance (α) of 0.05 and a variance of
1.0, we were able to detect differences in growth character-
istics of 0.048 SDS and 0.054 SDS respectively. First, dif-
ferences in allele distribution between children born SGA
(from the SGA cohort) and non-SGA subjects (from Gen-
eration R) were assessed. Differences were calculated
using the Chi-square test. Second, we examined the differ-
ences in birth characteristics between genotype groups
with linear regression analyses assuming an additive
model. Weight, length and head circumference at birth
and at different ages were analyzed using gender and age
adjusted standard deviation scores (SDS) [27,28]. Stand-
ard deviation scores were obtained using Dutch reference
growth curves (Growth Analyser 3.0, Dutch Growth
Research Foundation). For Generation R, we used the first
length SDS and head circumference SDS measured after
birth and before the second month of life, since these
measurements were not available at birth. Third, we com-
pared fetal (only Generation R) and postnatal characteris-
tics between the genotypes with linear regression analyses.
Finally, to assess longitudinally measured weight and
length patterns from fetal life to infancy, we performed
repeated measures regression analysis in both cohorts
with weight and length from birth to 24 months as out-
come variables. This regression technique takes the corre-
lation of multiple measurements within one subject into
account, assesses both the time-independent and time-
dependent effect of TCF7L2 genotype on growth, and
allows for incomplete outcome data [29]. In these mod-
els, genotype was included as both intercept and interac-
tion with age. To account for (gestational) age at each
specific measurement, these analyses were conducted
with age-adjusted standard deviation scores. The models
can be written as:
In this model, the term including 'β0' reflects the intercept
and the term including 'β1' reflects the slope of growth
(weight or length) per week for the reference group (CC
genotype). The terms including 'β2' and 'β3' reflect the age
independent growth differences in weight (and length)
between the different categories of the TCF7L2 genotype
respectively [30]. All models were unadjusted (all growth
characteristics are age and gender adjusted SD scores)
since population genotype distribution is assumed to be
unrelated to covariates and the effect estimates were not
materially affected by adjusting for maternal age, pre-
pregnancy body mass index or parity [31]. The occurrence
of gestational diabetes in the entire cohort was 0.6% and
did not affect the effect estimates. Therefore, occurrence of
gestational diabetes was not included in the analyses.
All effect estimates are presented with their 95% confi-
dence interval (95% CI). Statistical analyses were per-
formed using the Statistical Analysis System version 9.1.3
(SAS, Stata corporation, College Station, TX, USA), includ-
ing the PROC MIXED module for unbalanced repeated
measurements as well as the Statistical Package of Social
Sciences version 15.0 for Windows (SPSS Inc, Chicago, IL,
USA).
Results
Subject characteristics of Generation R and SGA cohort are
presented in Table 1. The minor allele frequency distribu-
tions did not differ significantly (p = 0.47) between non-
SGA subjects (from Generation R) (T-allele: 28.7%) and
the SGA cohort (T-allele: 29.8%) (Table 2).
No significant differences between genotype groups were
observed in fetal growth characteristics in Generation R
Height SDS  or weight SDS age  genotype( ) ( ) * *= + +
+
b b b0 1 2 7 2TCF L
b3 7 2* * .TCF L  genotype age
β β β
β
Table 1: Subject characteristics by cohort.
Characteristics Generation R The SGA cohort
Gender (% boys) 50.8% 47.2%
Gestational age (weeks) 40.1 (36.7 – 42.4) 38.0 (29.9 – 41.0)
Birth weight (grams) 3513 (511) 1819 (716)
Premature (gestational age < 37 weeks) (%) 2.9% 44.9%
Birth weight < 2500 grams (%) 2.5% 82.7%
Small for gestational age (weight <-2 SDS) (%) 0.9% 100%
Gestational diabetes (%) 0.6% N/A
Values are means (SD), medians (95% range) or percentages. N/A = not availablePage 4 of 8
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cumference, length and weight), between genotype
groups were observed in either cohort (Table 4). Postnatal
growth characteristics for both cohorts are shown in Table
5. No significant differences were found in either cohort
for head circumference, weight or height at any age.
Finally, no differences were found in weight growth rate
(SDS/year) from birth until the age of 2 years in either
Generation R or the SGA cohort. Compared to the CC
genotype, differences were -0.014 (95% confidence inter-
val (CI): -0.064, 0.036) SDS/year and -0.028 (95% CI: -
0.057, 0.002) SDS/year, for the CT and TT genotype,
respectively, in Generation R. In the SGA cohort, differ-
ences were -0.134 (95% CI: -0.376, 0.108) SDS/year and
0.002 (95% CI: -0.125, 0.129) SDS/year, for the CT and
TT genotype, respectively, using the CC genotype as a ref-
erence. Similarly, no differences were found in height
growth rate from birth to 2 years in either cohort (data not
shown).
Discussion
In the current study, we found that T2D gene polymor-
phism TCF7L2 rs7903146 is not associated with growth in
fetal life in the general population or with growth in early
postnatal life in either the general population or in a
cohort of subjects born SGA. We also confirmed previous
suggestions that this variant of TCF7L2 is not associated
with birth weight and, more importantly, demonstrated
that it does not influence the fetal development using
direct fetal measurements. Finally, we showed that this
polymorphism does not appear to be associated with the
risk of being born SGA.
To our knowledge, this study is the first to examine the
association of TCF7L2 with longitudinally measured
growth patterns in fetal and early postnatal life in two
independent birth cohorts. In the Generation R Study,
DNA for genotyping was available in 59% of all subjects
and was isolated from cord-blood. Missing cord-blood
was mainly caused by logistical restraints at delivery. Chil-
dren who were not genotyped had a shorter gestational
age (p < 0.001) and were lighter at birth (p < 0.001) than
subjects who were genotyped. Of all genotyped eligible
subjects at baseline, 22% did not participate in follow-up
measurements. In the SGA cohort, genotyping was suc-
cessful in 91% of the subjects and longitudinally growth
data were available in 48% of the cohort. Our effect esti-
mates could be biased if the associations between geno-
types and growth characteristics differed between those
with and without postnatal growth data available. In the
Generation R cohort, no differences were observed
between children with and without postnatal growth
measurements. In the SGA cohort the T-allele was slightly
more frequent in subjects with postnatal growth measure-
ments than in subjects without these measurements (p <
0.05). Finally, it could be possible that there is differential
effect of genotype on growth according to availability of
follow-up data. This bias would affect our estimates,
though such a bias seems unlikely.
Several studies have investigated the effect of common
genetic variants related to insulin action and secretion on
early growth [14,15,32,33]. Of the initially identified T2D
gene polymorphisms identified by the GWA, fetal
CDKAL1 (rs7754840) and HHEX (rs1111875) genotype,
and maternal TCF7L2 (rs7903146) genotype have been
Table 2: Distribution of TCF7L2 rs7903146 minor allele 
frequency according to cohort.
Allele frequency
C-Allele T-Allele p-value
Non-SGA (Generation R) (%) 4828 (71.3) 1948 (28.7)
SGA (SGA cohort) (%) 795 (70.2) 337 (29.8) 0.49
Non-SGA = All subjects from Generation R, excluding SGA subjects
SGA = birth weight SDS and/or birth length SDS <-2
p-value express differences in distribution between SGA and General 
population tested with Chi-square test.
Table 3: Fetal characteristics according to fetal TCF7L2 rs7903146 genotype in the Generation R study.
CC
(n = 1736)
CT
(n = 1329)
TT
(n = 301)
p-value#
Fetal characteristics second trimester
Head circumference (SDS) 0.04 (1.0) 0.02 (1.0) 0.05 (0.9) 0.88
Femur length (SDS) -0.01 (1.0) -0.01 (1.0) 0.05 (0.9) 0.64
Estimated fetal weight (SDS) -0.06 (1.0) -0.07 (1.0) 0.00 (1.0) 0.57
Fetal characteristics third trimester
Head circumference (SDS) 0.11 (1.0) 0.13 (1.0) 0.15 (0.9) 0.45
Femur length (SDS) 0.01 (1.0) -0.02 (1.0) -0.04 (1.0) 0.34
Estimated fetal weight (SDS) 0.12 (1.0) 0.14 (1.0) 0.11 (0.9) 0.99
Values are means (SD). SDS = standard deviation score for age and gender.
# p-values for additive models. Differences were tested using linear regression analyses.Page 5 of 8
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the Helsinki Birth Cohort that fetal TCF7L2 genotype did
not interact with birth weight to increase the risk of T2D
in adulthood [15].TCF7L2 rs7903146 has been shown to
have the strongest genetic effect on T2D and this result has
been replicated in several studies [3-5]. Therefore, TCF7L2
is a very important candidate gene for explaining the asso-
ciation between low birth weight and T2D risk. Our study
is the first to investigate the effect of TCF7L2 rs7903146
on longitudinal growth in early life. Longitudinal assess-
ment of growth provides more information than just
measurements at birth as we have demonstrated earlier
that different fetal growth patterns may result in a similar
birth weight [17]. Furthermore, most SGA born children
have catch-up growth during the first months of life but
15% remain small [34]. Thus, to investigate whether
TCF7L2 rs7903146 influences fetal and postnatal growth,
longitudinal growth data provide more information than
birth weight alone.
Table 4: Birth characteristics in both cohorts according to TCF7L2 rs7903146 genotype of child.
Generation R CC
(n = 1762)
CT
(n = 1351)
TT
(n = 306)
p-value#
Gestational age (weeks) n = 3419 40.3 (36.7 – 42.3) 40.3 (36.6 – 42.4) 40.1 (37.1 – 42.6) 0.83
Birth head circumference (SDS)* n = 2314 0.22 (0.9) 0.24 (0.9) 0.26 (0.9) 0.55
Birth length (SDS)* n = 1959 -0.07 (1.0) -0.08 (1.0) 0.00 (1.1) 0.66
Birth weight (SDS) n = 3419 0.21 (1.0) 0.22 (1.0) 0.20 (1.0) 0.97
SGA Cohort CC
(n = 270)
CT
(n = 255)
TT
(n = 41)
p-value#
Gestational age (weeks) n = 566 38.0 (28.6 – 42.0) 38.0 (28.6 – 41.0) 38.0 (29.0 – 42.0) 0.57
Birth head circumference (SDS) n = 203 -1.51 (1.4) -1.20 (1.6) -1.31 (1.4) 0.32
Birth length (SDS) n = 491 -3.11 (1.4) -3.27 (1.5) -3.02 (1.5) 0.41
Birth weight (SDS) n = 566 -2.40 (1.0) -2.46 (0.9) -2.32 (0.9) 0.58
* Length and head circumference were measured in the first two months of after birth.
Values are means (SD) or medians (95% range). SDS = standard deviation score for age and gender.
# p-values for additive models. Differences were tested using linear regression analyses.
Table 5: Postnatal characteristics at 6, 12, and 24 months according to TCF7L2 rs7903146 genotype.
Generation R CC
(n = 1375)
CT
(n = 1063)
TT
(n = 237)
p-value#
6 months Head circumference (SDS) -0.02 (0.93) -0.03 (0.89) -0.06 (0.91) 0.83
n = 2675 Height (SDS) 0.03 (0.91) 0.03 (0.90) 0.07 (0.93) 0.81
Weight (SDS) 0.41 (0.96) 0.44 (0.95) 0.54 (0.99) 0.14
12 months Head circumference (SDS) 0.00 (0.89) -0.04 (0.94) -0.03 (1.12) 0.54
n = 2559 Height (SDS) -0.01 (0.90) -0.05 (0.90) -0.01 (0.90) 0.70
Weight (SDS) 0.18 (0.98) 0.18 (0.99) 0.24 (1.00) 0.63
24 months Height (SDS) -0.19 (0.93) -0.21 (0.89) -0.18 (0.87) 0.82
n = 2445 Weight (SDS) -0.11 (0.99) -0.13 (1.00) -0.09 (0.96) 0.87
SGA cohort CC
(n = 143)
CT
(n = 107)
TT
(n = 22)
6 months Head circumference (SDS) -1.38 (0.92) -1.36 (0.90) -1.74 (1.04) 0.41
n = 272 Height (SDS) -2.39 (1.37) -2.43 (1.26) -2.51 (1.55) 0.93
Weight (SDS) -2.18 (1.40) -2.22 (1.26) -2.37 (2.05) 0.86
12 months Head circumference (SDS) -1.21 (0.83) -1.24 (0.88) -1.72 (1.06) 0.16
n = 268 Height (SDS) -2.25 (1.25) -2.30 (1.06) -2.30 (1.47) 0.94
Weight (SDS) -2.14 (1.41) -2.25 (1.15) -2.17 (1.89) 0.82
24 months Head circumference (SDS) -1.10 (0.82) -1.13 (0.87) -1.60 (1.06) 0.20
n = 244 Height (SDS) -2.39 (1.24) -2.47 (1.05) -2.94 (1.04) 0.20
Weight (SDS) -2.19 (1.33) -2.31 (1.21) -3.06 (1.65) 0.04
Values expressed as mean (SD). SDS = standard deviation score for age and gender.
# p-values for additive models. Differences were tested using linear regression.Page 6 of 8
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fetal and maternal risk allele [14]. They concluded that the
most likely mechanism for this association was that
maternal genotype was associated with a reduction of
maternal insulin secretion, leading to increased fetal glu-
cose and insulin levels and subsequently increased birth
weight, rather than a direct effect of the fetal genotype on
birth weight. Pulizzi et al. found no effect of the fetal gen-
otype of this polymorphism on birth weight. Since fetal
and maternal genotypes are 50% correlated, it cannot be
excluded that, when the risk allele is present in both
mother and child, small effects of fetal genotype that
reduce fetal growth could be masked by opposing effects
of maternal genotype. Since maternal genotype was not
available in our study, we were not able to test this
hypothesis. However, we did not find any effect of fetal
genotype on birth weight in the general population nor in
a specific population of children with insufficient fetal
growth resulting in small size for gestational age at birth.
Our findings are therefore in line with the conclusions of
these previous studies. Furthermore, we found no effect of
fetal genotype on estimated fetal weight or weight during
infancy, indicating that there is no evidence for any asso-
ciation between this fetal genotype and weight or change
in weight during early life either. The effect of this poly-
morphism on the metabolic phenotype found in adults
would therefore appear to develop after early childhood.
Nonetheless, our results also could be explained by a lack
of power and we cannot rule out that we were unable to
detect smaller effects of this variant on early growth.
Regarding intra-uterine growth retardation, an earlier
study examined the effect of TCF7L2 rs7903146 genotype
on SGA. Cauchi et al. found no association between this
genotype and SGA, using family-based association analy-
ses in over 3,000 subjects of which 627 subjects were SGA
[16]. In this analyses, the SGA group was slightly larger
than in our current study and included parents, but post-
natal growth data were not analyzed longitudinally. In
our study, we did not find a difference in minor allele fre-
quency between the general population (Generation R)
and the SGA cohort. On the basis of two independent and
negative studies, one may conclude that there is no asso-
ciation between this genetic polymorphism and risk of
SGA.
Conclusion
In summary, our results suggest that TCF7L2 rs7903146
does not influence growth from early fetal life to infancy.
Furthermore, minor allele frequency was not different in
SGA subjects than in non-SGA subjects, indicating that it
is unlikely that this polymorphism is associated with the
risk of being born SGA. Systematic searches for common
genetic variants by means of genome-wide association
studies will enable us to obtain a more complete under-
standing of which genes are involved in growth in fetal life
and infancy.
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